RARE DISEASERESEARCH ATLAS

ORPHA:517

Acute myelomonocytic leukemia

medium confidenceDisorder

Also known as: AML M4 · AMMoL

Publications

3,516

94th percentile

Trials

73

Interventional, condition-specific

Researchers

1,363

Distinct authors in sample

Gene link

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare acute myeloid leukemia disorder characterized by increased blast cells (myeloblasts, monoblast, and/or promonoblasts), representing more than 20% of the total bone marrow (BM) or peripheral blood differential counts, with 20-80% of BM cells being of monocytic lineage. Clinical presentation is the result of bone marrow involvement and extramedullary infiltration by the leukemic cells and includes asthenia, pallor, fever, dizziness, respiratory symptoms, easy bruising, bleeding disorders, and neurological deficits. Gingival hyperplasia, organomegaly, especially , and lymphadenopathy may also be associated.

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (7)

AMML · acute M4 myeloid leukaemia · acute M4 myeloid leukemia · acute myelomonocytic leukaemia · acute myelomonocytic leukaemia (FAB type M4) · acute myelomonocytic leukemia · acute myelomonocytic leukemia (FAB type M4)

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    3,516 matched papers (1,298 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    73 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

3,516

3,516 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

3,516 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

1,298 in the last 10 years · medium confidence · 94th percentile (publications denominator)

Phrase hits: 3,516 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,363

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Li J5 papers · 2026

    Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

    Papers in Europe PMC
  2. 02
    Li X5 papers · 2026

    Shaanxi Key Laboratory of High-Orbits-Electron Materials and Protection Technology for Aerospace, School of Advanced Materials and Nanotechnology, Xidian University, Xi'an, Shaanxi 710126, China.

    Papers in Europe PMC
  3. 03
    Liu Y5 papers · 2026

    Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing 400037, People's Republic of China.

    Papers in Europe PMC
  4. 04
    Zhang J4 papers · 2025

    The Second Department of General Surgery, the Fourth Hospital of Hebei Medical University, Hebei, Shijiazhuang, China.

    Papers in Europe PMC
  5. 05
    Zhang X4 papers · 2025

    Key Laboratory of Basic and New Drug Research of Tradinonal Chinese Medicine, Shaanxi Universily of Chinese Medicine, Xianyang, Shaanxi 712046, China.

    Papers in Europe PMC
  6. 06
    Haferlach T3 papers · 2025

    MLL Munich Leukemia Laboratory, Munich, Germany.

    Papers in Europe PMC
  7. 07
    Li F3 papers · 2026

    Department of Hematology and Oncology, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, 250022, China.

    Papers in Europe PMC
  8. 08
    Li H3 papers · 2025

    Center for Biomedical-photonics and Molecular Imaging, Advanced Diagnostic-Therapy Technology and Equipment Key Laboratory of Higher Education Institutions in Shaanxi Province, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710126, China; Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education & Xi'an Key Laboratory of Intelligent Sensing and Regulation of Trans-Scale Life Information, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi 710126, China.

    Papers in Europe PMC
  9. 09
    Li Y3 papers · 2022

    Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Hematology of Nanjing Medical University.

    Papers in Europe PMC
  10. 10
    Liu Z3 papers · 2026

    Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. liuzhenfang@gxmu.edu.cn.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

73

interventional trials for this specific condition

73 interventional trials matched this specific condition name; none in our sample are currently recruiting.

Data as of 27 July 2026

73 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 98th percentile).

medium confidence · 98th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

73 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Observational and natural-history studies

3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Acute myelomonocytic leukemia" OR "AML M4" OR "AMMoL" OR "acute M4 myeloid leukaemia" OR "acute M4 myeloid leukemia" OR "acute myelomonocytic leukaemia" OR "acute myelomonocytic leukaemia (FAB type M4)" OR "acute myelomonocytic leukemia (FAB type M4)"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Acute myelomonocytic leukemia" OR "AML M4" OR "AMMoL" OR "acute M4 myeloid leukaemia" OR "acute M4 myeloid leukemia" OR "acute myelomonocytic leukaemia" OR "acute myelomonocytic leukaemia (FAB type M4)" OR "acute myelomonocytic leukemia (FAB type M4)"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 73 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: AMML

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T14:08:29.080Z